

## PARTICIPATING FACULTY

### *Targeting HPV: The Power of Prevention*

This supplement to *The American Journal of Managed Care* provides participants with a review of human papillomavirus vaccination. This supplement has been reviewed by an expert in the field.

---

#### *Faculty*

**Matthew M. Davis, MD, MAPP**

Associate Professor of Pediatrics,  
Internal Medicine, and Public Policy  
University of Michigan  
C.S. Mott Children's Hospital  
Division of General Pediatrics  
Ann Arbor, Michigan

**Amanda F. Dempsey, MD, PhD, MPH**

Instructor, Division of Pediatrics  
Child Health Evaluation and Research  
(CHEAR) Unit  
Division of General Internal Medicine  
University of Michigan  
Ann Arbor, Michigan

**Eduardo L. Franco, DrPH, MPH**

Professor of Epidemiology and Oncology  
Director, Division of Cancer Epidemiology  
Department of Oncology  
McGill University  
Montreal, Quebec, Canada

**Pamela Ann Hymel, MD, MPH**

Corporate Director, Integrated Health  
Medical Director  
Cisco Systems  
San Jose, California

**Helen Trottier, PhD, MSc**

Postdoctoral Fellow  
Division of Cancer Epidemiology  
Department of Oncology  
McGill University  
Montreal, Quebec, Canada

---

## *Disclosure Statement*

In accordance with the ACCME and the ACPE, participants for this activity have completed conflict-of-interest statements.

In compliance with the Health Insurance Portability and Accountability Act standards, no presentations in this CME/CE activity shall disclose the names or other identifiers of patients referenced without a signed waiver from the identified patient.

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

These participants report relationships with the following pharmaceutical companies:

■ **Amanda F. Dempsey, MD, PhD, MPH**

*Speakers' bureau for:*  
Merck

■ **Eduardo L. Franco, DrPH, MPH**

*Grant support from:*  
Merck

*Consultant fees from:*  
GlaxoSmithKline  
Merck

The following participants have declared no financial affiliations with corporate organizations:

■ **Matthew M. Davis, MD, MAPP**

■ **Pamela Ann Hymel, MD, MPH**

■ **Helen Trottier, PhD, MSc**

### **Investigational and/or Off-label Use of Commercial Products and Devices**

The University of Cincinnati College of Medicine requires all faculty to disclose any discussion of investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside US Food and Drug Administration–approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

The faculty claim not to discuss any investigational and/or off-label use of a pharmaceutical product or device.

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Princeton, New Jersey.

**Editor's note:** Mention of trade names and particular pharmaceutical companies in this supplement is for the reader's reference only. Promoting any pharmaceutical company or its commercial interests should not be inferred.

## *Targeting HPV: The Power of Prevention*

### **GOAL**

To increase understanding of the etiologic role of human papillomavirus (HPV) in development of cervical cancer and other diseases, the potential for HPV vaccination to reduce the risk of these clinical sequelae, and the burden on the healthcare system.

### **TARGET AUDIENCE**

This activity is intended for physicians, medical directors, pharmacists, pharmacy directors, primary care physicians, and other managed care decision makers.

### **LEARNING OBJECTIVES**

After completing this continuing education activity, the participant should be able to:

- Describe the epidemiology of HPV and the burden that cervical cancer and other HPV-related disease put on the healthcare system
- Discuss the safety and efficacy of HPV vaccines and their potential impact on disease burden and healthcare costs
- Identify parent, provider, and other potential barriers to HPV vaccine implementation and some possible ways to address these concerns.

### **CONTINUING MEDICAL EDUCATION ACCREDITATION**

The University of Cincinnati College of Medicine designates this educational activity for a maximum of two (2) *AMA PRA Category 1 CME credit(s)*<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in this activity.

The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor medical education for physicians.

**Release Date: December 1, 2006. Expiration Date: December 1, 2007.**

### **CONTINUING PHARMACY EDUCATION ACCREDITATION**

*Pharmacy Times/Ascend Media* Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEUs) under the ACPE universal program number of 290-999-06-018-H01.

**Release Date: December 1, 2006. Expiration Date: December 1, 2007.**

### **FUNDING**

This program is supported by an educational grant from **GlaxoSmithKline**.



The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.